Akebia Therapeutics (AKBA) Misses Q2 EPS by 9c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.60), $0.09 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $49.81 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen